Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

From the Design to the Clinical Application of Thromboxane Modulators

Author(s): Jean-Michel Dogne, Julien Hanson, Xavier de Leval, Domenico Pratico, Cecil R. Pace-Asciak, Pierre Drion, Bernard Pirotte and Ke-He Ruan

Volume 12, Issue 8, 2006

Page: [903 - 923] Pages: 21

DOI: 10.2174/138161206776055921

Price: $65


Arachidonic acid (AA) metabolites are key mediators involved in the pathogenesis of numerous cardiovascular, pulmonary, inflammatory, and thromboembolic diseases. One of these bioactive metabolites of particular importance is thromboxane A2 (TXA2). It is produced by the action of thromboxane synthase on the prostaglandin endoperoxide H2 (PGH2) which results from the enzymatic transformation of AA by the cyclooxygenases. It is a potent inducer of platelet aggregation, vasoconstriction and bronchoconstriction, and has been involved in a series of major pathophysiological conditions. Therefore, TXA2 receptor antagonists, thromboxane synthase inhibitors and drugs combining both properties have been developed by different laboratories since the early 1980s. Several compounds have been launched on the market and others are under clinical evaluation. In the first part of this review, we will describe the physiological properties of TXA2, thromboxane synthase and thromboxane receptors. The second part is dedicated to a description of each class of thromboxane modulators with the advantages and disadvantages they offer. In the third part, we aim to describe recent studies performed with the most interesting thromboxane modulators in major pathologies: myocardial infarction and thrombosis, atherosclerosis, diabetes, pulmonary embolism, septic shock, preeclampsia, and asthma. Each pathology will be systematically reviewed. Finally, in the last part we will highlight the latest perspectives in drug design of thromboxane modulators and in their future therapeutic applications such as cancer, metastasis and angiogenesis.

Keywords: prostaglandin, Thromboxane synthase, GP IIb/IIIa binding sites, isoprostanes, Thrombosis, ICAM-1

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy